• Logo
  • SBMUJournals

Febuxostat Promoted Dissolution of Radiolucent Nephrolithiasis in Patients with Hyperuricemia

Mao Yunhua, Zhang Hao, Li Ke, Huang Wentao, Li Xiaokang, Situ Jie



Purpose: This study aimed to investigate the efficacy and safety of febuxostat in patients with radiolucent nephrolithiasis.

Materials and Methods: From March 2016 to June 2018, data of 96 patients with radiolucent nephrolithiasis and hyperuricemia who referred to the Third Affiliated Hospital of Sun Yat-sen University were retrospectively analyzed. These patients were divided into allopurinol 300mg/d (control), febuxostat 40mg/d (F40) and 80mg/d (F80) groups respectively. All patients took potassium citrate as a combination treatment and had been followed up for at least 6 months. Before treatment and on the day of the 1st, 3rd and 6th month, complete blood count, serum uric acid (sUA), hepatic and renal function as well as ultrasound were carried out, arthritic and gastrointestinal symptoms were monitored. Computed tomography was measured before treatment and 6 months after medication.

Results: 31, 29 and 30 patients were included in the final analysis of treatment efficacy respectively. Compared with allopurinol group, F40 group showed no difference in urate-lowering effect, while F80 had the best effect across all the visits (P<0.01). At 6th month, 25(83.3%) cases of F80 group achieved sUA<6mg/dL, which was better than allopurinol group (18 cases, 58.1%) and F40 group (17 cases, 58.6%). In the dissolution effect of radiolucent calculi, F80 had the best effect, followed by F40 and then allopurinol (P<0.05). No statistical difference was observed in adverse events among three groups.

Conclusion: Febuxostat significantly decreased sUA, promoted radiolucent stone dissolution and reduced the total stone number, whereas it didn’t increase the adverse events.


Nephrolithiasis, hyperuricemia, febuxostat, allopurinol


Coe FL, Kavalach AG. Hypercalciuria and hyperuricosuria in patients with calcium nephrolithiasis. N Engl J Med. 1974; 291(25):1344-1350.

Spivacow FR, Del Valle EE, Lores E, et al. Kidney stones: Composition, frequency and relation to metabolic diagnosis. Medicina (B Aires). 2016; 76(6):343-348.

Moe OW, Xu LHR. Hyperuricosuric calcium urolithiasis. J Nephrol. 2018. 31(2):189-196.

Goldfarb DS, MacDonald PA, Gunawardhana L, et al. Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones. Clin J Am Soc Nephrol. 2013.8(11):1960-1967.

Trinchieri A, Montanari E. Prevalence of renal uric acid stones in the adult. Urolithiasis. 2017; 45(6):553-562.

Ma Q, Fang L, Su R, et al. Uric acid stones, clinical manifestations and therapeutic considerations. Postgrad Med J. 2018;94(1114):458-462.

Heilberg IP. Treatment of patients with uric acid stones. Urolithiasis. 2016; 44(1):57-63.

Soskind R, Abazia DT, Bridgeman MB. Updates on the treatment of gout, including a review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares. Expert Opin Pharmacother. 2017;18(11):1115-1125.

Cicerello E. Uric acid nephrolithiasis: An update. Urologia. 2018;85(3):93-98.

Capasso G, Jaeger P, Robertson WG, et al. Uric acid and the kidney: urate transport, stone disease and progressive renal failure. Curr Pharm Des. 2005; 11(32):4153-4159.

Zhou Q, Su J, Zhou T, et al. A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study. Int J Clin Pharmacol Ther. 2017;55(2):163-168.

Takano Y, Hase-Aoki K, Horiuchi H, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci 2005;76(16):1835-1847.

Ettinger B, Tang A, Citron JT, et al. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med. 1986; 315(22):1386-1389.

Arowojolu O, Goldfarb DS. Treatment of calcium nephrolithiasis in the patient with hyperuricosuria. J Nephrol. 2014; 27(6):601-605.

Rizvi SAH, Hussain M, Askari SH, et al. Surgical outcomes of percutaneous nephrolithotomy in 3402 patients and results of stone analysis in 1559 patients. BJU Int. 2017;120(5):702-709.

Mandel NS, Mandel IC, Kolbach-Mandel AM. Accurate stone analysis: the impact on disease diagnosis and treatment. Urolithiasis. 2017; 45(1):3-9.

Dalbeth N, Stamp L: Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial. 2007;20(5):391-395.

Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep. 2009;11(2):135-140.

Jordan A, Gresser U. Side Effects and Interactions of the Xanthine Oxidase Inhibitor Febuxostat. Pharmaceuticals (Basel). 2018; 11(2).

White WB, Saag KG, Becker MA, et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018; 378(13):1200-1210.

Zhang M, Solomon DH, Desai RJ, et al. Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol. Circulation. 2018;138(11):1116-1126.

DOI: http://dx.doi.org/10.22037/uj.v0i0.5564


  • There are currently no refbacks.